"Non-compliance with MS treatment procedures remains a major challenge," explains Deepika. "Establishing end-user confidence has become difficult due to unsatisfactory therapeutic results."
Cumbersome and painful procedures discourage the progress of therapy. Simple advances, like the use of oral drugs instead of injections, will prove beneficial to promoting compliance with therapeutic regimes.
"Awareness raising through public healthcare forums and organisations about new developments and innovative treatment options will contribute toward establishing greater end-user confidence," concludes Deepika. "In the meantime, precautionary measures like adopting healthy lifestyle practices will help limit the incidence of the disease."
If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at firstname.lastname@example.org.
Analysis of the European Multiple Sclerosis is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Global Generics Market and European Autoimmune Diseases Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies.
|SOURCE Frost & Sullivan|
Copyright©2010 PR Newswire.
All rights reserved